DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Pediatrics
SEARCH
Aktueller Standort:
>
>
> This Story

Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

Cardiology Homepage

Philips extends advanced automation capabilities on its EPIQ CVx cardiology ultrasound platform

Acutus Medical announces $170 million financing

Phoenix Children's will soon open newly-equipped cardiovascular intensive care unit (CVICU)

Simple scan could direct treatments for angina

Philips receives FDA premarket approval for its HeartStart OnSite and HeartStart Home defibrillators

DIGISONICS receives ASE certification for the ImageGuideEcho Registry

RAPID by iSchemaView now available for use in Mexico

Guerbet announces group purchasing agreement with Premier to distribute novel microcatheters

Merit Medical acquires Brightwater Medical

Keynote speakers for the opening day of its annual scientific session this September in Chicago

HeartFlow planner changes treatment strategy in nearly half of patients with coronary heart disease

Press releases may be edited for formatting or style
REDWOOD CITY, Calif.--(BUSINESS WIRE)--HeartFlow, Inc., today announced new data demonstrating that the use of the investigational HeartFlow Planner, a real-time, non-invasive interactive planning tool, led to a change in treatment strategy in 45% of patients with coronary artery disease (CAD) and reduced the need for invasive physiology. The data from the BOWIE (Benefits of Obtaining information for planning With noninvasive FFRCT prior to Invasive Evaluation) study were presented by Eric Van Belle, M.D., Ph.D., Professor of Cardiology, Head of the Lille Heart & Lung Institute, and principal investigator for BOWIE, as a late-breaking trial at the EuroPCR Conference in Paris, France.

“The BOWIE results highlight the potential benefit of using a real-time interactive tool prior to a revascularization procedure as it can help inform the treatment plan, optimize completeness of revascularization, and streamline resource utilization in the cath lab,” said Campbell Rogers, M.D., Chief Medical Officer, HeartFlow.

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED



BOWIE is a retrospective study that included 101 patients. Three interventional cardiologists independently reviewed the diagnostic angiogram for each patient and provided a treatment recommendation. The same three interventional cardiologists then reviewed each patients’ HeartFlow Analysis and used the HeartFlow Planner to virtually explore different treatment scenarios and provide a treatment recommendation. The study compared the differences in recommended treatment plans.

For example, in one case, the interventionalists initially recommended that a lesion be treated with a 38mm stent based on the diagnostic angiogram. After reviewing different treatment options with the HeartFlow Planner, the interventionalists changed the recommendation to treat the lesion with a 15mm stent as the reduced stent length demonstrated a similar physiologic effect.

The HeartFlow Planner is an interactive tool that enables interventional cardiologists and heart teams to modify vessels virtually, and thereby determine the optimal treatment strategy prior to an invasive procedure. Every HeartFlow Analysis case is accompanied by enough data to allow HeartFlow Planner to modify vessel narrowings and arrive at a personalized ideal anatomical model, and to allow additional computations based on altered flow rates resulting from modified vessels. With HeartFlow Planner, an interventional cardiologist or heart team can explore the treatment area and view the modified vessel and resulting FFRct changes in real time. This tool allows non-invasive study of treatment scenarios to identify which intervention is optimal. The HeartFlow Planner is currently not available for commercial use and is under review with the U.S. Food and Drug Administration (FDA).
  Pages: 1 - 2 >>

Cardiology Homepage


You Must Be Logged In To Post A Comment

E-Mail-Werbung
Erhöhen Sie Ihren Bekanntheitsgrad
Auktionen + Privatverkäufe
Den besten Preis erzielen
Geräte/Geräteteile kaufen
Den günstigsten Preis finden
Daily News
Die neuesten Nachrichten lesen
Übersicht
Alle DOTmed Benutzer durchsuchen
Ethik auf DOTmed
Unseren Ethik-Standard anzeigen
Gold-Parts Verkäufer-Programm
PH-Anfragen erhalten
Gold Service Dealer-Programm
Anfragen empfangen
Gesundheitsdienstleister
Alle Gesundheitsdienstleister-Tools anzeigen
Jobs/Training
Einen Job suchen
Parts Hunter +EasyPay
Angebote für Geräteteile erhalten
Kürzlich zertifizierte Benutzer anzeigen
Kürzlich zertifizierte Benutzer anzeigen
Kürzlich auf DOTmed bewertet
Kürzlich zertifizierte Benutzer anzeigen
Rental Central
Geräte billiger mieten
Geräte/Geräteteile verkaufen
Das meiste Geld erhalten
Servicetechniker
Hilfe und Beratung finden
Einfache Angebots-Anfrage
Angebote für Geräte erhalten
Virtuelle Messe
Service für Geräte finden
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2019 DOTmed.com, Inc.
ALL RIGHTS RESERVED